It’s Biotech Season! Five Deals to Raise $611 Million.
The Biotech IPO Queue Grows Longer as Five More Companies File (Xconomy)
Alkero Therapeutics, $86 Million.Prevail Therapeutics, $100 Million.Dermavant Sciences, $100 Million.BridgeBio, $225 Million. Atreca,...
StHealth Capital, Our #1 Ranked Emerging BDC Idea.
Newly Launched Medtech & Biotech BDC Seeking Pre-IPO Stage Investments.
This is easily one of the most exciting fund managers we've come across in a...
StHealth Private Equity Medtech Fund. Alternative Investment BDC.
StHealth Capital (STHC, no symbol yet) has put together an amazing team to manage the Fund recently organized to provide investors with both yield...
Former Tesla Foundation Vice Chairman Joins StHealth BDC.
St Health Capital Investment Corporation is delighted to announce Dr. Robert GW Brown FAPS, FIEE, FInstP, MAE as a key new member to our board of directors.
Dr....
Hercules BDC (HTGC) $13, to Present at FB Riley.
Hercules Capital to Discuss 2019 Growth Opportunities at the B. Riley FBR Institutional Investor Conference
PALO ALTO, Calif.--(BUSINESS WIRE)-- Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the...
Innovus (INNV) in Silicon Review Interview.
POISED FOR INNOVATION.
The Silicon Review is the world’s most trusted online and print community for business & technology professionals. Our community members include thought-provoking...
Innovus (INNV) Conference Call Transcript.
Q1 2019 Results, 5/15/19.
Innovus Pharmaceuticals, Inc. (OTCQB:INNV) Q1 2019 Earnings Conference Call May 15, 2019 4:15 PM ET
Company Participants
Bassam Damaj - President and CEO
Ryan...
Innovus (INNV): Twenty-Eight Drugs in Five Years. (San Diego Reader)
(Originally published 4/25/2018)
“I am very steady. I like to work slowly, but surely, to get to my goal.” Thus speaks Bassam Damaj, president and...
Adding Innovus Pharma (INNV) $2.50 to Watch List.
Fast Growing eCommerce and Direct to Consumer Pharma Company Announces 1st Foray into CBD and 2nd Major Off-Patent Blockbuster Drug to its lineup.
We're adding...
Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.
CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided...
Latest article
Latest Research Report: $20 Price Target from Greenridge Global.
Here are four research reports below to peruse, all with price targets $20.00 or more...
While we don't issue price targets, it's comforting to see...
Three More Companies Suspended by SEC!
Millions of Investor's Dollars are Being Trapped.
These three companies had a combined market cap of $563 million at the time they were halted, whose...
AI Data Center Short – Jim Chanos
“If the economic life on these things is three years ... the whole economics of a lot of these deals kind of falls...
